JPRN-UMIN000010688已完成2 期
Random Phase II Study of Effectiveness of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy in the Patients with Gynecologic Malignancy - Random Phase II Study of Laftidine and Pregabalin for Paclitacel-Induced Peripheral Neuropathy
Kansai Clinical Oncology Group0 个研究点目标入组 80 人开始时间: 2013年7月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.ECOG performance status: 3 or 4 2.Patients with neuropathy due to apparently other causes such as diabetes 3.Patients who have received more than two previous chemotherapy regimen 4.Patients with moderate to severe renal dysfunction (serum creatinine >1.5mg/ml, or creatinine clearance <30ml/min) 5.Patients with severe congestive heart failure 6.Patients with angioedema 7.Patients who have been administered laftidine or pregabalin previously for peripheral neuropathy 8.Patients taking any antidepressants or any anticonvulsants 9.Patients for whom completion of this study is deemed inappropriate for any reason
研究者
相似试验
招募中
不适用
A pilot study to evaluate the efficacy of lafutidine in patients with paclitaxel-induced peripheral neuropathy.gynecological cancerJPRN-UMIN000011890Fukushima medical University Hospital, School of medicine30
已完成
不适用
Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. GLICO-0801-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-059-09Grupo Latinoamericano de Investigaciones Clinicas en Oncologica (GLICO),
已完成
不适用
Early effects of oral administrations of lafutidine with mint oil on intragastric pHHealty male volumteerJPRN-UMIN000001864Gastroenterology Division, Yokohama City University Graduate School of Medicine10
招募中
2 期
A feasibility study to evaluate the utility of a drug (lenalidomide) for preventing recurence in patients with Primary central nervous system lymphoma.This study will use a drug called lenalidomide for 2 years after completion of standard treatment with aim of preventing recurences.CTRI/2019/04/018546Tata Memorial Center
进行中（未招募）
1 期
Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphomaPrimary central nervous system or Intra ocular lymphoma in relapse or refractory to previous treatmentMedDRA version: 14.1Level: LLTClassification code 10051811Term: Cerebral lymphomaSystem Organ Class: 100000004864EUCTR2012-003786-17-FRINSTITUT CURIE45